Salud financiera de hoja de balance de Pieris Pharmaceuticals

Salud financiera controles de criterios 4/6

Pieris Pharmaceuticals tiene un patrimonio de los accionistas total de $26.8M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $38.7M y $11.9M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$26.37m
Patrimonio	US$26.76m
Total pasivo	US$11.92m
Activos totales	US$38.68m

Actualizaciones recientes sobre salud financiera

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($38.7M) de PI6 superan a sus pasivos a corto plazo ($11.9M).

Pasivo a largo plazo: PI6 no tiene pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: PI6 está libre de deudas.

Reducción de la deuda: PI6 no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: PI6 tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: PI6 tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 28% cada año

Salud financiera de hoja de balance de Pieris Pharmaceuticals

Salud financiera controles de criterios 4/6

Información clave

Actualizaciones recientes sobre salud financiera

Pieris Pharmaceuticals Approves 1-for-80 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement

Recent updates

Pieris Pharmaceuticals Approves 1-for-80 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement

Full year 2023 earnings released: US$0.27 loss per share (vs US$0.45 loss in FY 2022)

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: US$0.11 loss per share (vs US$0.13 loss in 3Q 2022)

Insufficient new directors

Pieris Pharmaceuticals, Inc. Announces Executive Changes

New major risk - Financial position

Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference

First quarter 2023 earnings released: US$0.18 loss per share (vs US$0.069 loss in 1Q 2022)

Pieris Pharmaceuticals, Inc. Announces Successful Completion of Safety Review for 10 Mg Dose of Phase 2A Trial of Elarekibep (Prs-060/Azd1402)

Full year 2022 earnings released: US$0.45 loss per share (vs US$0.71 loss in FY 2021)

Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of Cd228 X 4-1Bb Bispecific Molecule (Mabcalin Sgn-Bb228 (Prs-346)

Insufficient new directors

Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.24 loss in 3Q 2021)

Pieris Pharmaceuticals, Inc. Announces Dosing of First Subject in Phase 1 Trial of Inhaled CTGF Inhibitor PRS-220

Second quarter 2022 earnings released: US$0.14 loss per share (vs US$0.25 loss in 2Q 2021)

Pieris Pharmaceuticals, Inc. Announces Tim Demuth Steps Down as Senior Vice President and Chief Medical Officer, Effective September 30, 2022

First quarter 2022 earnings released: US$0.069 loss per share (vs US$0.074 loss in 1Q 2021)

Pieris Pharmaceuticals, Inc., Annual General Meeting, Jun 22, 2022

Insufficient new directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Pieris Pharmaceuticals, Inc. Announces Successful Completion of Safety Milestone and Initiation of Efficacy Portion of Phase 2A Trial of PRS-060/AZD1402

Third quarter 2021 earnings released: US$0.24 loss per share (vs US$0.26 loss in 3Q 2020)

Insufficient new directors

Second quarter 2021 earnings released: US$0.25 loss per share (vs US$0.095 loss in 2Q 2020)

Pieris Pharmaceuticals, Inc.(NasdaqCM:PIRS) dropped from Russell 3000E Growth Index

First quarter 2021 earnings released: US$0.074 loss per share (vs US$0.065 loss in 1Q 2020)

Full year 2020 earnings released: US$0.68 loss per share (vs US$0.56 loss in FY 2019)

Pieris Pharmaceuticals, Inc. announced that it expects to receive $10.000002 million in funding from AstraZeneca PLC

Pieris Pharmaceuticals, Inc. announced that it has received $13.008671 million in funding

New 90-day low: €1.99

New 90-day high: €2.47

Third quarter 2020 earnings released: US$0.26 loss per share

Revenue misses expectations

New 90-day low: €1.94

Earnings released

New 90-day low - €2.16

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera